-16.1%

-5.8%Business EPS(1)euro 1.66-10.8%-16.1%-6.0%In order to facilitate an understanding of our operational performance, we comment on our business net income statement. Business net income(1) is a non-GAAP financial measure. The consolidated income statement for Q1 2011 is provided in Appendix 8. A reconciliation of business net income to consolidated net income is provided in Appendix 7. Consolidated net income in Q1 2011 was euro 1,218 million (compared with euro 1,714 million in Q1 2010) and included a non-recurring charge of euro 325 million net of tax corresponding to the amortization of Merial assets that would have been recognized for the period from September 18, 2009 to December 31, 2010, had these assets not been classified as held for sale or exchange. Consolidated earnings per share in Q1 2011 was euro 0.93 versus euro 1.31 in Q1 2010.

Commenting on the Group's performance in Q1 2011, sanofi-aventis Chief Executive Officer, Christopher A. Viehbacher said, "This quarter, the year-on-year comparison must take into account the absence of non-recurring A/H1N1 sales. I'm particularly satisfied with the performance of our growth platforms which were up 15.5% (excluding A/H1N1) and now represent almost 60% of Group sales; these businesses have compensated for the impact of generic competition on net sales and represent the future of our company. As of this quarter, we now fully consolidate Merial, our animal health division which delivered a strong performance. We have also closed the Genzyme transaction and the integration phase has started favorably." Q1 2011 Performance